Deucravacitinib
- Generic Name
- Deucravacitinib
- Brand Names
- Sotyktu
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O3
- CAS Number
- 1609392-27-9
- Unique Ingredient Identifier
- N0A21N6RAU
- Background
Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target. This selectivity towards TYK2 may lead to an improved...
- Indication
Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is not recommended for use in combination with other potent immunosuppressants.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
- Associated Therapies
- -
Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT05997277
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 756
- Registration Number
- NCT05946941
- Locations
- 🇯🇵
Institute of Science Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
🇩🇪Charite University Hospitals, Berlin, Germany
🇵🇹Instituto Portugues de Reumatologia, Lisboa, Portugal
Correction of Psoriatic T Cell Signatures by Deucravacitinib
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 25
- Registration Number
- NCT05858645
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Deucravacitinib in PG
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT05821374
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1500
- Registration Number
- NCT05744466
- Locations
- 🇺🇸
Local Institution, Waltham, Massachusetts, United States
Deucravacitinib for the Treatment of Palmoplantar Pustulosis
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT05710185
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 180
- Registration Number
- NCT05701995
- Locations
- 🇺🇸
Local Institution - 0006, Phoenix, Arizona, United States
🇺🇸Local Institution - 0034, Scottsdale, Arizona, United States
🇺🇸Local Institution - 0015, North Little Rock, Arkansas, United States
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 490
- Registration Number
- NCT05620407
- Locations
- 🇧🇷
Local Institution - 0033, Curitiba, Brazil
🇧🇷Hospital São Lucas de Copacabana, Rio de Janeiro, Brazil
🇧🇷Hospital Alemao Oswaldo Cruz, São Paulo, Brazil
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
- Conditions
- Interventions
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 490
- Registration Number
- NCT05617677
- Locations
- 🇷🇴
Hightech Medical Services SRL-Centrul pentru Studiul Metabolismului, Bucharest, București, Romania
🇵🇹Local Institution - 0073, Lisbon, Portugal
🇺🇸Nouvelle Clinical Research, Cutler Bay, Florida, United States
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 94
- Registration Number
- NCT05556265
- Locations
- 🇺🇸
Local Institution - 0013, Houston, Texas, United States
🇵🇱Local Institution - 0025, Warsaw, Poland
🇺🇸Local Institution - 0012, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.